You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Colorcon
Harvard Business School
Baxter
Johnson and Johnson

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,731,963

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,731,963 protect, and when does it expire?

Patent 8,731,963 protects XYREM and is included in one NDA.

Protection for XYREM has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 8,731,963
Title:Sensitive drug distribution system and method
Abstract: A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.
Inventor(s): Reardan; Dayton T. (Shorewood, MN), Engel; Patti A. (Eagan, MN), Gagne; Bob (St. Paul, MN)
Assignee: Jazz Pharmaceuticals, Inc. (Palo Alto, CA)
Application Number:13/592,202
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,731,963
Patent Claim Types:
see list of patent claims
Use; Process;

Drugs Protected by US Patent 8,731,963

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Jazz Pharms XYREM sodium oxybate SOLUTION;ORAL 021196-001 Jul 17, 2002 AA RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Express Scripts
Mallinckrodt
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.